Cancer Immunology Research’s New Editors-in-Chief Ready to Showcase Immuno-oncology’s Next Wave
Elizabeth M. Jaffee and Antoni Ribas will look to feature the next wave of immuno-oncology advances as Cancer Immunology Research's...
Elizabeth M. Jaffee and Antoni Ribas will look to feature the next wave of immuno-oncology advances as Cancer Immunology Research's...
Experts reflected on how clinical decision-making for treating breast cancer may change in light of the latest results shared...
The AACR Cancer Progress Report 2024 detailed the connection between alcohol consumption and the increased risk of certain cancers....
At the San Antonio Breast Cancer Symposium, experts discussed the implications of sexual health, supplements, exercise, and diet for...
In the final three months of 2024, the FDA issued 15 approvals in oncology, including several therapies that are...
This month, the editors of the AACR journals highlighted studies about the gut microbiome in lung cancer, modeling the...
In 2024, the American Association for Cancer Research (AACR) released the 14th edition of the annual AACR Cancer Progress...
A session on molecular degraders at SABCS 2024 highlighted an exciting new frontier for SERDs, PROTACs, LYTACs, and biparatopic...
By Vivek Subbiah, MD, Sarah Cannon Research Institute It is both the best of times and a challenging time...
Researchers at the 2024 San Antonio Breast Cancer Symposium discussed considerations for treating and managing of early-onset breast cancer.
When the chemotherapy drug 5-fluorouracil (5-FU) was approved in 1962, there was limited understanding of how it is metabolized...